A new Israeli test for lung cancer allows doctors to catch the disease while patients still have a good chance of recovery.
The Israeli company Savicell has developed a successful blood test for lung cancer, allowing the disease to be detected and treated in its earliest stages, thus boosting the chances of recovery.
Dr. Shafrira Shai — the development and production manager of Savicell — was quoted by the Hebrew news outlet Mako as saying, “This process in fact identifies the energetic profile of the cells created as a result of their specific reactions. This gives us exact information on the condition of the person, if he’s in pre-cancerous condition, the beginning stages of cancer, or other possibilities.”
Eyal Davidovitch — the company’s vice president of operations — emphasized the importance of the new test.
“Statistics indicate that if you discover lung cancer in an early stage, the chances of recovery wander on average between 50-80 percent,” he said. “If you identify it at a late stage, we’re talking about four percent — it’s unbelievable. Lung cancer is the number one killer.”